ICCC Q3 2019 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+37.9% YoY

Gross Profit

$1M48.9% margin

Operating Income

-$429,816-14.5% margin

Net Income

-$502,535-16.9% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+9.6%

Cash Flow

Operating Cash Flow

-$66,406

Free Cash Flow

-$466,287

Stock-Based Comp.

$68,653

Balance Sheet

Total Assets

$39M

Total Liabilities

$10M

Stockholders' Equity

$29M

Cash & Equivalents

$2M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+37.9%
Gross Profit	$1M	$950,967	+52.6%
Operating Income	-$429,816	-$149,140	-188.2%
Net Income	-$502,535	-$249,956	-101.0%